|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1; encoded by the SERPINE1 gene), a u-PA inhibitor and antifibrinolytic agent, is often elevated in obesity and is linked to cardiovascular events.
|
31054988 |
2019 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Obesity and the metabolic syndrome are associated with prothrombotic changes, which have been well characterized and related to complex adipocyte-induced inflammatory changes, including increased levels of plasminogen activator inhibitor type 1, von Willebrand factor, fibrinogen, and other evidence of increased coagulation and platelet activation.
|
29986373 |
2018 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Obesity is associated with prothrombotic changes which have been well-characterised and include increased levels of plasminogen activator-1, von Willebrand factor, fibrinogen and evidence of increased coagulation and platelet activation; however, these changes do not seem to account for all the increased risk.
|
28262235 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.
|
28378106 |
2017 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The following were also associated: smoking with AT, PC, and alcoholism; obesity with Plg; smoking with alcoholism, and PS deficiency.
|
26315791 |
2015 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity?
|
20514421 |
2010 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies using a nutritionally induced obesity model in transgenic mice support a role of the fibrinolytic (plasminogen/plasmin) and matrix metalloproteinase (MMP) systems in these processes.
|
19151845 |
2009 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relatively strong positive associations were seen with markers of inflammation, including CD68, macrophage chemoattractant protein-1, and plasminogen activator inhibitor (PAI)-1 mRNA (r >/= 0.46, P = 0.001 for each), that remained significant after controlling for BMI and S(i).
|
18057090 |
2008 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
An association between an increase in plasminogen activator inhibitor type 1 and obesity has been described.
|
18037477 |
2008 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that the gene expression of renin-angiotensin system components, together with that of plasminogen activator inhibitor (PAI)-1, is upregulated in the liver of patients with obesity and type 2 diabetes.
|
18078928 |
2008 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, at the translational level, significant positive, but weak associations were determined for obesity (P -/+ 0.037), age (P -/+ 0.038), uric acid (P < 0.001), body mass index (P -/+ 0.01), plasminogen (P -/+ 0.013), and fibrinogen (P -/+ 0.002) in bivariate regression analyses, whereas HDL-cholesterol (P -/+ 0.005) was shown to be negatively correlated.
|
15319168 |
2005 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
An association between an increase in plasminogen activator inhibitor type 1 (PAI-1) and obesity, and also between elevated levels of PAI-1 and the presence of PAI-1 promoter 4G allele has been described in adults and can contribute to increased risk of cardiovascular disease.
|
11522017 |
2001 |